Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Less Is More: FDA May Narrow Risk Info In Rx Drug TV Ads

Executive Summary

Agency is considering whether drug broadcast ads should note only risks that are severe, serious or actionable; FDA study finds this limitation improves risk recall and recognition of benefits.

You may also be interested in...



Bill Would Make US FDA Issue Final Rule On Risk Information In Broadcast DTC Ads

Proposed rule issued in March 2010 requires ‘major statement’ on a drug’s side effects in ‘a clear, conspicuous, and neutral manner’ for TV and radio ads. Bill would mandate a final rule within six months.

Rx Drug Ads: New US FDA Studies Target Accelerated Approval Information

Upcoming research projects will look at presentation of FDA approval status, timing of disease awareness ads, and healthcare professional views.

Rx Promotion Citations By US FDA Plummet; UCLA Webpage Elicits Final Letter Of 2017

Last year's record low five letters came as FDA launched flurry of studies on DTC, professional ads; 'Bad Ad' complaints totaled more than 100.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS121355

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel